Collaborations - Additional Information (Details) $ in Thousands, ¥ in Millions					1 Months Ended						10 Months Ended	12 Months Ended
	Oct. 31, 2021 USD ($)	Oct. 31, 2021 JPY (¥)	Jan. 01, 2019 USD ($)	Jan. 01, 2019 JPY (¥)	Jan. 31, 2023	Dec. 31, 2022 USD ($)	Dec. 31, 2022 JPY (¥)	Jul. 31, 2022	Jun. 30, 2020 USD ($)	May 31, 2020 USD ($)	Oct. 31, 2021	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jan. 01, 2023 USD ($)	Jan. 01, 2023 JPY (¥)	Dec. 31, 2022 JPY (¥)	Jun. 23, 2020 shares
Common Shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Shares issued upon exercise of warrants outstanding | shares																	750,000
Ono Pharmaceutical Co., Ltd. | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration term extended period											1 year
Second amendment agreement					In January 2023, the Company and Ono entered into a second amendment to the Ono Agreement whereby the Research Term, as defined in the Ono Agreement, was extended until July 31, 2023.
Non-refundable upfront payment received						$ 8,100						$ 8,100
Initial nonrefundable upfront fee payment received			$ 8,100	¥ 900
Initial upfront fee payment			1,000	110
Collaboration receivable						1,500						1,500				¥ 200
Deferred revenue, additions	$ 900	¥ 100				1,500	¥ 200
Milestone payments entitled to be received						6,500						6,500		$ 3,400	¥ 450	750
Deferred revenue, current						10,500						10,500	$ 9,000
Ono Pharmaceutical Co., Ltd. | Research, Development and Regulatory Milestones | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial nonrefundable upfront fee payment received			$ 7,100	¥ 790
Ono Pharmaceutical Co., Ltd. | Commercial Milestones | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received						149,500						149,500				¥ 17,210
Ono Pharmaceutical Co., Ltd. | Grant of License [Member] | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received														900	¥ 110
Research service payments entitled to be received, total														$ 4,300
Bristol-Myers Squibb Company
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment received						50,000						50,000
Bristol-Myers Squibb Company | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment received										$ 50,000
Initial nonrefundable upfront fee payment received									$ 50,000
Collaboration term expiration period										42 months
Deferred revenue						27,400						27,400	42,500
Deferred revenue, current						27,400						27,400	2,900
Deferred revenue, noncurrent						0						0	39,600
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received										$ 301,000
Bristol-Myers Squibb Company | Research, Development and Regulatory Milestones | Collaboration and License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received										176,000
Bristol-Myers Squibb Company | Commercial Milestones | Collaboration and License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received										$ 125,000
Bristol-Myers Squibb Company | Product Research Activity | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognized												2,700	1,100
Bristol-Myers Squibb Company | Product RPTX Options to License Druggable Target | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognized												12,500	6,500
Hoffmann La Roche Inc And F Hoffmann La Roche Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment received						134,626						134,626
Hoffmann La Roche Inc And F Hoffmann La Roche Ltd | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment received						134,600						134,600
Initial nonrefundable upfront fee payment received												125,000
Collaboration Revenue Received						4,000						4,000
Estimated period of completion of trials to get revenue								24 months
Deferred revenue recognized												116,600
Deferred revenue						18,000						18,000	0
Deferred revenue, current						15,300						15,300	0
Deferred revenue, noncurrent						2,700						2,700	$ 0
Hoffmann La Roche Inc And F Hoffmann La Roche Ltd | Commercial Milestones | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestones payments												1,172,000
Hoffmann La Roche Inc And F Hoffmann La Roche Ltd | Additional Clinical Development Plan | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration Revenue Received						4,000						4,000
Hoffmann La Roche Inc And F Hoffmann La Roche Ltd | Clinical Trial Materials | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration Revenue Received						5,600						5,600
Deferred revenue recognized												2,700
Hoffmann La Roche Inc And F Hoffmann La Roche Ltd | Research and Development Services | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognized												8,600
Hoffmann La Roche Inc And F Hoffmann La Roche Ltd | Combined Licenses
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment received						$ 105,327						105,327
Hoffmann La Roche Inc And F Hoffmann La Roche Ltd | Combined Licenses | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognized												$ 105,300